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Changing geographical patterns and trends in cancer 
incidence in children and adolescents in Europe, 1991–2010 
(Automated Childhood Cancer Information System): 
a population-based study
Eva Steliarova-Foucher, Miranda M Fidler, Murielle Colombet, Brigitte Lacour, Peter Kaatsch, Marion Piñeros, Isabelle Soerjomataram, 
Freddie Bray, Jan Willem Coebergh, Rafael Peris-Bonet, Charles A Stiller, on behalf of the ACCIS contributors*
Summary
Background A deceleration in the increase in cancer incidence in children and adolescents has been reported in 
several national and regional studies in Europe. Based on a large database representing 1∙3 billion person-years over 
the period 1991–2010, we provide a consolidated report on cancer incidence trends at ages 0–19 years.
Methods We invited all population-based cancer registries operating in European countries to participate in this 
population-based registry study. We requested a listing of individual records of cancer cases, including sex, age, date 
of birth, date of cancer diagnosis, tumour sequence number, primary site, morphology, behaviour, and the most valid 
basis of diagnosis. We also requested population counts in each calendar year by sex and age for the registration area, 
from official national sources, and specific information about the covered area and registration practices. An eligible 
registry could become a contributor if it provided quality data for all complete calendar years in the period 1991–2010. 
Incidence rates and the average annual percentage change with 95% CIs were reported for all cancers and major 
diagnostic groups, by region and overall, separately for children (age 0–14 years) and adolescents (age 15–19 years). 
We examined and quantified the stability of the trends with joinpoint analyses.
Findings For the years 1991–2010, 53 registries in 19 countries contributed a total of 180 335 unique cases. We excluded 
15 162 (8·4%) of 180 335 cases due to differing practices of registration, and considered the quality indicators for the 
165 173 cases included to be satisfactory. The average annual age-standardised incidence was 137∙5 (95% CI 
136∙7–138∙3) per million person-years and incidence increased significantly by 0∙54% (0∙44–0∙65) per year in children 
(age 0–14 years) with no change in trend. In adolescents, the combined European incidence was 176∙2 (174∙4–178∙0) 
per million person-years based on all 35 138 eligible cases and increased significantly by 0·96% (0∙73–1∙19) per year, 
although recent changes in rates among adolescents suggest a deceleration in this increasing trend. We observed 
temporal variations in trends by age group, geographical region, and diagnostic group. The combined age-standardised 
incidence of leukaemia based on 48 458 cases in children was 46∙9 (46∙5–47∙3) per million person-years and increased 
significantly by 0∙66% (0∙48–0∙84) per year. The average overall incidence of leukaemia in adolescents was 
23∙6 (22∙9–24∙3) per million person-years, based on 4702 cases, and the average annual change was 0∙93% 
(0∙49–1∙37). We also observed increasing incidence of lymphoma in adolescents (average annual change 1·04% 
[0·65–1·44], malignant CNS tumours in children (average annual change 0·49% [0·20–0·77]), and other tumours in 
both children (average annual change 0·56 [0·40–0·72]) and adolescents (average annual change 1∙17 [0∙82–1∙53]).
Interpretation Improvements in the diagnosis and registration of cancers over time could partly explain the observed 
increase in incidence, although some changes in underlying putative risk factors cannot be excluded. Cancer 
incidence trends in this young population require continued monitoring at an international level.
Funding Federal Ministry of Health of the Federal German Government, the European Union’s Seventh Framework 
Programme, and International Agency for Research on Cancer.
Copyright This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any 
use of this article, there should be no suggestion that WHO endorses any specific organisation, products, or services. 
The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.
Introduction
Cancer is an important disease burden in children as it is 
not easily prevented, with known causes explaining only a 
small proportion of cases. In Europe, incidence rates 
range from 140–170 per million person-years (ie, number 
of incident cases divided by the number of person-years 
at risk) in populations younger than 15 years and from 
180–240 per million in those aged 15–19 years.1 During 
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the past three decades, incidence increased by about 
1% per annum for all cancers combined and this increase 
affected most major diagnostic groups, including 
leukaemias, lymphomas, and CNS tumours.2 However, in 
the past decade, incidence appears to have stabilised 
overall and for the major diagnostic groups in European 
populations.3–10
Leukaemias, lymphomas, and tumours of the CNS 
represent 70% of all cancers observed in European 
populations younger than 15 years and half of all cancers 
in those aged 15–19 years1 and therefore contribute 
considerably to the overall incidence. Changing incidence 
could result from numerous factors, including variations 
in diagnostic capacity, completeness of registration, 
population composition, and exposure to risk factors. 
Monitoring these trends is important for planning 
health-care delivery and for aetiological research.
In this study, we documented and interpreted incidence 
trends in Europe for cancers diagnosed at ages 0–19 years 
using quality-assured population-based cancer registries. 
We focused on the 20-year period 1991–2010, assessing 
the trends separately in children (aged 0–14 years) and 
adolescents (aged 15–19 years), for all cancers combined 
and for the major diagnostic groups. Our results update 
the Automated Childhood Cancer Information System 
(ACCIS) studies, extending the previously reported 
period of observation by over a decade.2,11
Methods
Data acquisition
We invited all population-based cancer registries 
operating in European countries (as defined by the UN 
Statistics Division12) and Cyprus to participate in this 
population-based registry study. We requested a listing of 
individual records of cancer cases, and the population in 
each calendar year by sex and age from official national 
sources, accompanied by specific information about the 
geographical and administrative area covered and 
registration practices.
Information on cancer cases included coded data on 
sex, age, date of birth, date of diagnosis, tumour sequence 
number, primary site, morphology, behaviour, and the 
most valid basis of diagnosis. Most registries coded 
tumours according to the International Classification of 
Diseases for Oncology, Third Edition (ICD-O-313) as 
required, and International Classification of Diseases for 
Oncology, Second Edition14 codes were converted to 
ICD-O-3 codes. Subsequently, neoplasms were classified 
according to the International Classification of Childhood 
Cancer, Third Edition (ICCC-3).15 We examined individual 
records for internal consistency,16 verifying unlikely 
combinations of site with morphology, age or sex with 
tumour type, basis of diagnosis with morphology, and 
rare tumour entities. The proportions of cases micro-
scopically verified, identified from death certificate only, 
or with unknown basis of diagnosis and unspecified 
morphology contributed to data evaluation. The ACCIS 
Scientific Committee assessed the distribution of new 
cases across years and plausibility of case mix and age 
distribution. Standardised tables, charts, statistics, lists of 
selected questioned records, and any relevant information 
provided by the registry or known from published sources 
were discussed at meetings of the ACCIS Scientific 
Committee, who decided on the inclusion of each dataset 
in the ACCIS database. Only datasets with high-quality 
data were eligible for inclusion in the analyses.
The cancers included in the analyses were all malignant 
tumours diagnosed during the complete calendar years 
1991–2010, in people younger than 20 years and resident 
in the contributing registration areas. Several cancer 
types were excluded because they were not eligible for 
registration in all participating registries or during the 
whole study period: myelodysplasias (ICD-O-3 M-codes 
starting with 998), pilocytic astrocytoma (ICD-O-3 code 
For more on ACCIS see 
http://accis.iarc.fr/
Research in context
Evidence before this study
We searched PubMed with no language restrictions to identify 
studies published since Jan 1, 2004, that investigated cancer 
incidence trends in children (age 0–14 years) and adolescents 
(age 15–19 years) in Europe and other high-income countries, 
using the search terms ‘child* cancer incidence trends’ and 
‘adolescen* cancer incidence trends’. Evidence from retrieved 
studies suggested that after a substantial increase in childhood 
cancer incidence towards the end of the last century, the rate of 
increase has declined in the 2000s. However, the limitations of 
most of these studies, in terms of number of cases or 
timeframe, might have hampered the full understanding of the 
dynamisms behind the observed trends in this population.
Added value of this study
We used all quality data available in Europe for the full calendar 
years in the period 1991–2010 to evaluate incidence patterns 
and trends in children and adolescents. Overall, incidence 
continued to increase during the study period by 0∙5% per year 
in children and 1∙0% per year in adolescents. However, we 
observed some evidence of a deceleration in increasing cancer 
trends, modulated by age group, European region, and 
diagnostic group. Based on the large scale of all available 
European data, our findings add an authoritative account on 
the geographical patterns and temporal trends of cancer in 
children and adolescents in Europe. 
Implications of all the available evidence
The increasing trends might have resulted from improvements 
in cancer diagnosis or registration in this age group, although the 
influence of other factors cannot be excluded. The paucity of 
evidence of stabilisation of cancer incidence in Europe and the 
variability of the observed trends support the need for continued 
international monitoring and research into causal mechanisms.
Articles
www.thelancet.com/oncology   Vol 19   September 2018 1161
M-9421), non-melanoma skin cancer (ICCC-3 subgroup 
XIe and XIIb with site code C44), and carcinoid tumour 
of the appendix (ICD-O-3 site code C18.1 and M-8240).
The data used in this study were submitted and validated 
during the years 2015–16. Our study design was reviewed 
and approved by the International Agency for Research on 
Cancer (IARC) Ethics Committee on June 17, 2015.
Dataset constitution
An eligible registry could become a contributor if it 
provided quality data for all complete calendar years in 
the 20-year period 1991–2010. The 53 contributing 
registries in 19 countries (appendix p 2) included nine 
paediatric registries. The paediatric registries collected 
and provided data for those aged 0–14 years, and the 
other cancer registries and the paediatric registry of 
Belarus provided data for the full target age range 
(0–19 years). The French national paediatric registry 
registered haematological malignancies only.
Some populations in France, Germany, Italy, Spain, 
Switzerland, and the UK were covered by both paediatric 
and general cancer registries. To avoid double counting of 
cases in two registries while using the maximum number 
of cases for analyses in these populations, we allocated 
each registry to one or more datasets (appendix p 2). We 
built three datasets—one with 39 registries contributing 
to the analyses of all cancers, CNS tumours, and other 
tumours in ages 0–14 years, a second with 32 registries 
contributing to the analyses of leukaemia and lymphoma 
in ages 0–14 years, and a third with 45 registries 
contributing to all the analyses of those aged 15–19 years. 
The first and second datasets (ages 0–14 years) differed 
only in the contribution from France; the analyses of all 
cancers and CNS tumours used a dataset that included 
data from the French general cancer registries, while the 
leukaemia and lymphoma dataset included data from the 
French national paediatric registry of haematological 
malignancies. The French national registry increased the 
person-years by ten times and provided 11 770 more 
haematological malignancies compared with the 
combined contribution of the French regional registries.
Subnational numbers of cases and person-years were 
pooled to produce national cancer incidence and countries 
were further pooled into four European regions (appendix 
p 2) according to UN definitions.12 The person-years 
available in each region are shown in the appendix (p 3).
Statistical analysis
The number of incident cases in the covered areas of the 
participating registries during the study period determined 
our sample size. Incidence was calculated as the number 
of cases divided by the number of person-years in the 
categories of geographical area, sex, age, and diagnostic 
group for the given 20-year period and expressed per 
million person-years. As the age distribution of population 
at risk differs between countries and over time, we 
adjusted the reported incidence for the age range 0–14 years 
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for age via direct standardisation using weights 12, 10, 
and 9 for the three age groups 0–4 years, 5–9 years, 
and 10–14 years, respectively.17 We also calculated 95% CIs. 
As each combination of calendar year, sex, and age group 
had a positive person-years count, we encountered no 
missing data.
To graphically portray incidence trends for all cancers, 
we plotted observed incidence against calendar year for 
each country, and the rates for the four European regions 
were smoothed using a locally weighted regression18 of 
the incidence on year.
To assess the average annual percentage change, we fit 
the natural logarithm of the incidence with year using 
generalised linear regression models adjusting for age 
group and region, as appropriate. We quantified changes 
in incidence as the average annual percentage change, 
with corresponding 95% CIs. The null hypothesis 
corresponded to no change in the annual rate, which was 
Figure 1: Incidence trends of cancer in children aged 0–14 years in Europe, 1991–2010
Jagged thin lines indicate annual age-standardised rates in countries and smooth red thick lines indicate modelled incidence trends in regions.
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equivalent to 0 lying within the 95% CI for the average 
annual percentage change. We analysed each cancer 
category, overall and by European region, using Stata 
(version 14). We examined incidence trends for changes 
during the study period using Joinpoint Regression 
Program (version 4.1.0) applied to the log rates, separately 
for the age groups 0–14 years and 15–19 years in the total 
dataset, and in each cancer category, overall and by region. 
The null hypothesis assumed the annual percentage 
change was constant throughout the study period. We 
used the permutation test19 to determine the number of 
joinpoints, by default set to a maximum of three for Europe 
and five for analyses adjusted for region. Where joinpoints 
were detected, we reported the annual percentage change 
with corresponding 95% CIs for each of the linear 
segments identified between two significant joinpoints.
Role of the funding source
The funders of the study external to the collaborating 
institutions had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. MC, MMF, and ES-F had full access to all 
the data used in the study. The corresponding author 
had final responsibility for the decision to submit for 
publication.
Results
During the full calendar years of the period 1991–2010, 
the 53 registries contributed 1∙3 billion person-years and 
180 335 unique cases. 15 162 (8·4%) of 180 335 cases were 
excluded, and the proportion of excluded cases varied 
slightly between age groups and regions. We considered 
the quality indicators for the 165 173 included cases to 
be satisfactory (appendix p 3). In 2010, the available 
population at risk represented 53·2 million (46·6%) of 
114·1 million of the European population aged 0–14 years 
and 9·8 million (22·6%) of 43·2 million aged 15–19 years, 
with reference to UN population estimates.20 In western 
Europe, coverage of the childhood population was almost 
complete for haematological malignancies (27·9 million 
[93·3%] of 29·9 million), and 17·5 million (58·5%) of 
29·9 million were covered for the other malignancies, 
while 2·1 million (20·1%) of 10·6 million adolescents 
were covered (appendix p 3).
We included all 118 265 eligible cases in patients aged 
0–14 years in our analyses of incidence of all cancers. 
Figure 2: Overview of observed incidence trends of cancer in children aged 0–14 years for the entire study period and for any time segments identified in joinpoint analysis, by diagnostic 
group and region of Europe, 1991–2010
Red indicates an increasing trend, blue indicates a decreasing trend, and white indicates no significant trend. Absence of bars indicates no joinpoint was identified for a given category.
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The average annual age-standardised incidence was 
137∙5 (95% CI 136∙7–138∙3) per million person-years 
and incidence increased significantly by 0∙54% 
(0∙44–0∙65) per year on average (table 1), with no break 
in the time trend. There was a large decrease in 
incidence for the national registry of Belarus, 
contributing to the regional pattern (figure 1). The large 
fluctuation of annual incidence in Iceland was due to 
small population size and did not visibly affect the 
shape of the regional curve (figure 1). The trend in the 
east was split into two segments, both with non-
significant trends (figure 2).
We investigated incidence for four diagnostic groups 
in patients aged 0–14 years (table 1, figure 2, appendix 
p 4), and included all eligible cases. The combined 
age-standardised incidence of leukaemia based on 
48 458 cases in patients aged 0–14 years was 46∙9 (95% CI 
46∙5–47∙3) per million person-years and increased by 
0∙66% (0∙48–0∙84) per year, with no change in slope. 
We observed an increase in each region, although only 
during the first decade in the north. The overall 
age-standardised incidence of lymphoma was 15∙8 
(15∙6–16∙0) per million person-years (based on 
18 458 cases) and varied modestly by region. Incidence 
increased in the west and decreased in the east, and we 
detected no change in the slopes. The overall age-
standardised incidence of malignant CNS tumours 
(19 413 cases) of 22∙2 (95% CI 21∙9–22∙6) per million 
person-years was observed to rise at 0∙49% (0∙20–0∙77) 
per annum with no joinpoints; by region, we observed 
an increasing trend only in the west, as the rates were 
stable in the three other regions.
In patients aged 0–14 years, the combined incidence of 
all 43 706 other cancers increased in Europe overall and 
in all regions except the north. In joinpoint analysis, the 
European trend increased only over the first few years, 
similar to the trend in the west (figure 2).
In adolescents (aged 15–19 years), the combined 
European incidence was 176∙2 (95% CI 174∙4–178∙0) per 
million person-years based on all 35 138 eligible cases 
and incidence increased by 0·96% (95% CI 0∙73–1∙19) 
per year in the period 1991–2010 (table 2), although no 
significant change in trend was seen in the second 
decade (figure 3). We investigated incidence trends by 
country and region, and regional trends by diagnostic 
group (figure 4, appendix p 5). In addition to large 
variations due to small numbers of cases for some 
countries, we observed a large range in incidence 
(between around 140 and 240 per million person-years) 
for Belarus. The slopes of trends in the regions were 
uneven, except in the south. In the east, a decrease was 
noted over the time segment 1999–2008  (figure 3).
For adolescents, the overall incidence of leukaemia was 
23∙6 (95% CI 22∙9–24∙3) per million person-years (based 
on all 4702 eligible cases) and varied little between 
regions (table 2). Incidence increased except in the north, 
where it was fairly stable, resulting in an average annual 
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change of 0∙93% (0∙49–1∙37). No change in the slopes 
was detected. Lymphoma (9446 cases) occurred more 
frequently than did leukaemia (4702 cases) or malignant 
CNS tumours (2983 cases) in adolescents compared with 
children (table 2), and the overall incidence of 47∙4 
(46∙4–48∙3) per million person-years varied moderately 
by region. An increase in incidence was observed for all 
European data combined and in all European regions 
investigated. Changes in this trend were detected in the 
east and west, where the increase was limited to the 
second and first half of the study period, respectively 
(figure 3). The overall age-specific incidence of malignant 
CNS tumours was 15∙0 (14∙4–15∙5) per million person-
years. Incidence was stable overall and in the four defined 
regions (figure 3), with no change in the slopes.
The overall rate for all other cancers in adolescents 
(18 007 cases) was 90∙3 per million. The European 
avearge annual change of 1∙17% (0∙82–1∙53) differed 
between three segments—among them a significant 
increase was detected during the first decade only. The 
pattern of changes in the slopes by region was similar to 
that observed for all cancers (figure 3).
Discussion
In this population-based registry study, we reported 
on cancer incidence trends in the European population 
of children (aged 0–14 years) and adolescents (aged 
15–19 years) during the full calendar years 1991–2010, 
thus extending the ACCIS study by 10–132,11 years of 
observation. The overall incidence for children and 
adolescents increased significantly over this 20-year 
period.
The increase in incidence was not constant by cancer 
type, region, or over time, and there was a suggestion of 
stabilisation in the trend for all cancers in adolescents 
in the dataset for the whole of Europe (appendix p 6). 
The most pronounced inter-regional diversities included 
the decreasing incidence of childhood lymphomas in 
the east (compared with stable or increasing incidence 
in the other regions), an increase in the incidence of 
childhood CNS tumours in the west (compared with 
little change observed in the other regions), and the 
stable incidence of leukaemia in adolescents in the 
north (relative to increasing incidence in the other 
regions).
Figure 3: Overview of observed incidence trends of cancer in adolescents aged 15–19 years for the entire study period and for any significant time segments identified in joinpoint analysis, by 
diagnostic group and region of Europe, 1991–2010
Red indicates an increasing trend, blue indicates a decreasing trend, and white indicates no significant trend. Absence of bars indicates no joinpoint was identified for a given category.
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Although our results are largely confirmatory and 
incremental from previous findings, a major strength of 
our study is its large size, which permits detection of a 
moderate rate of increase of 0∙5% per year in the age group 
0–14 years. Data from large paediatric cancer registries 
helped to increase the coverage and creation of a specific 
dataset for childhood haematological malignancies enlarged 
the relevant person-years in the west (583·8 million) by 
53% compared with data available for other neoplasms 
(380·5 million). We examined the trends separately in 
children and adolescents to allow for variations in trends 
between these populations with a different case mix.
Figure 4: Incidence trends of cancer in adolescents aged 15–19 years in Europe, 1991–2010
Jagged thin lines indicate annual age-specific rates in countries and smooth thick red lines indicate modelled incidence trends in regions.
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We validated the quality and completeness of the data 
from the included registries during a thorough dataset 
assessment. We consider our results to provide the 
best available estimates of incidence trends in the 
European population of children and adolescents for 
1991–2010.
A limitation of our study is the variable coverage of the 
regions, which might affect the representativeness of 
the incidence at the national and European regional 
levels. The available data do not allow speculation on 
what the incidence would be if coverage was complete—
increase of coverage and quality of registration is 
required for a full picture of the cancer burden. 
Meanwhile, by use of all quality information available for 
the study period, our results maximise the number of 
person-years of comparable data, and provide evidence of 
changing trends in European populations.
We excluded several cancer types that are usually 
included in reports of childhood cancer incidence from 
our analyses. The excluded cancer types are classified by 
the ICCC-314 and contribute to the total cancer burden, 
and it is therefore preferable that they are registered. 
In particular, exclusion of non-malignant CNS tumours 
might have shaped the observed trends. We plan to 
examine this assumption in a focused analysis of trends 
of all CNS tumours, by behaviour and diagnostic 
subgroup, and by considering the differences and 
changes in coding and their reportability.
Our reported total incidence was 5% to 15% lower 
(depending on the region) than in another report 
assessing the period 2001–10.1 This disparity is explained 
by the exclusion of several groups of neoplasms from our 
study and the period starting one decade earlier, which 
would, in the presence of an increasing trend, result in a 
lower overall rate.
The overall average annual change of 0∙54% in children 
aged 0–14 years is lower than the 1% reported by an 
ACCIS study based on diagnoses in the 1970s through to 
the 1990s2 or for the period 1978–97,21 and might indicate 
a deceleration in the increase of cancer incidence, 
although the registry datasets included differ somewhat 
between the studies. A lower rate of increase could 
suggest the end of an improvement in reporting, but 
might also reflect reduced reporting discipline, a change 
in classification of cancers, or other factors. Cancer-specific 
studies might provide more precise interpretation of 
these trends.
Studies in European populations of smaller sizes 
reported stabilising of cancer incidence in children 
overall and in the three major diagnostic groups.3–10 
By contrast, data collected in the longstanding registries 
of the Surveillance, Epidemiology, and End Results 
(SEER) Program suggest continued minor increases in 
overall childhood cancer incidence over the most 
recently assessed period 1995–2014,22 consistent with 
our study. In adolescents aged 15–19 years, varying 
incidence trends were observed in different European 
populations for leukaemia, lymphoma, or CNS 
tumours.3,4,7 As for the SEER data,22 our study found an 
increase in overall cancer incidence and leukaemia and 
lymphoma incidence, but no change in trends for 
malignant CNS tumours. A large US study23 reported 
stable incidence over the period 2001–09 overall and for 
the three major diagnostic groups in the population 
younger than 20 years. We identified changes in overall 
trends that provide some evidence of a deceleration 
of time trends during the most recent years of our 
study, along with varying patterns across age 
groups, regions, and cancer types, although significant 
joinpoints should not be taken to imply abrupt changes 
in underlying trends in risk.19 The variability we found 
warrants continued monitoring of incidence patterns 
in large populations over long periods, as trends that 
are not significant over short intervals might result in 
significant increases over a longer timeframe, and 
grouping smaller populations with no trend could 
yield a significant change in a pooled dataset. These 
considerations might also explain the discrepancy in 
the measured rate of change between our study and 
smaller European datasets.3–10
Kroll and colleagues24 have linked the increase in 
childhood cancer incidence in Great Britain with 
advances in diagnostic technology and improved cancer 
registration, because of the concurrence of a step 
increase in leukaemia and non-CNS solid tumour 
incidence in 2002 with a registration plan enacted in 
2001. Similarly, the rise in the incidence of CNS tumours 
in 1992 coincided with the introduction of innovative 
methods of diagnosis. As a result, childhood cancer 
might have been under-reported in Great Britain during 
parts of the period assessed in this study. Although we 
are not aware of similar studies in other countries, 
analogous effects on childhood cancer incidence cannot 
be excluded elsewhere in Europe and could have affected 
our results.
The gradual convergence of environmental factors, 
lifestyle, and health services across Europe might have 
contributed to the similarities in incidence trends across 
the regions, although such changes will probably have 
less of an effect on cancer in childhood than in older 
age. Nevertheless, some opposing trends (notably for 
lymphoma in the east) suggest caution should be taken 
in ascribing the slowly increasing trends exclusively to 
improved detection, at least before further detailed 
analyses by cancer type, age group, and geographical 
region are done.
Overall incidence in children is weighted towards 
leukaemia, which, in 75% of cases, is the precursor B-cell 
lymphoid leukaemia. The age-specific curve for this cancer 
type currently peaks around age 2–4 years in most 
high-income countries. With increasing social development 
over time, this peak shifts towards younger ages and 
becomes more pronounced.2,25 This change is unlikely to be 
driven by improved registration, which would affect all 
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ages in the same way. The deficit of lymphoid leukaemia 
cases seen in poorer settings can be ascribed in part to 
underdiagnosis,26,27 but inequalities across social strata 
might also operate through relevant exposures, such as 
parental occupation, diet, or reproduction characteristics.28 
Continuous socioeconomic development and increasing 
awareness of primary care practitioners might have 
contributed to the observed increase in leukaemia cases, 
although reasons for the stabilisation of leukaemia 
incidence in northern Europe are unclear.
Incidence of lymphoma was relatively high compared 
with incidence of leukaemia in children in eastern 
Europe. Considering the likely infectious origin of 
lymphoma at young ages,29 our observed decreasing 
incidence could be attributed to elimination of certain 
viral exposures. Furthermore, diagnosis of lymphoma 
might be delayed until older ages, especially if the 
decreasing trend in children is accompanied by an 
increasing trend in adolescents, as seen in the east over 
the second decade. Possible selective under-reporting 
could also be considered, as the incidence of leukaemia 
and other cancers continues to increase in children in 
the east. The high incidence in southern Europe is 
consistent with previous reports of possible environ-
mental exposures.30 A further assessment of lymphoma 
trends by diagnostic subgroups, narrower age groups, 
and sex could help provide a more specific explanation of 
the observed temporal changes.
The stability of malignant CNS tumour incidence in 
adolescents is encouraging, although drawing firm 
conclusions should be postponed until incidence trends 
are examined using data that include non-malignant 
tumours in the populations in which these are ascertained 
completely to exclude the possible effect of changes in 
classification of tumours. In children, because of the 
shown persisting increase in incidence in malignant CNS 
tumours, and the exclusion of non-malignant tumours—
specifically pilocytic astrocytoma—from our analyses, a 
further detailed assessment is warranted, especially 
considering the poor outcome for such tumours.
The trends for all other cancers combined show that 
the overall increase in incidence is not explained solely 
by changes in the three major groups of childhood and 
adolescent cancer. This fact is especially relevant in 
adolescents, as many cases are germ cell tumours and 
carcinomas.1 The candidate explanatory groups for the 
increase in at least a part of the period are thyroid 
carcinoma,31 testicular tumours,32 and melanoma.33 In 
particular, the patterns for Belarus are probably shaped 
by the pronounced increase and later waning of thyroid 
cancer incidence during the study period, reflecting 
exposure to the radioactive fallout from the Chernobyl 
accident.34 These observations also merit detailed studies.
In summary, in this study we aimed to provide an 
overview of cancer incidence trends in children and 
adolescents in Europe, as an introduction to a detailed 
investigation of patterns and trends and their possible 
determinants by diagnostic group and other subcategories 
in a concerted series of studies. We found a continued 
increase in cancer incidence in children and adolescents in 
Europe over the 20-year period 1991–2010. The diversity of 
trends across the regions and tumour groups warrants 
further monitoring and a more detailed assessment of the 
high-quality data collected by cancer registries, by specific 
tumour types and population subgroups. Whether the 
observed increase in cancer incidence in children and 
adolescents is due to enhanced discovery of cases or 
changing risk factors, the known frequency of cancer in 
young people should be considered in cancer control 
programmes. Without an accurate quantification of the 
possible causes of this increase, whether real or artifactual, 
it is prudent to continue aetiological research into the 
causes of cancer in children and adolescents and to explore 
possible preventive measures.
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